Evolus (NASDAQ:EOLS) Sets New 52-Week Low – Here’s What Happened

Shares of Evolus, Inc. (NASDAQ:EOLS) hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $10.16 and last traded at $10.21, with a volume of 505260 shares changing hands. The stock had previously closed at $10.74.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Evolus in a research note on Monday, September 16th. Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Evolus in a research report on Friday, September 13th. HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of Evolus in a research report on Thursday, November 7th. Finally, Barclays boosted their price target on shares of Evolus from $16.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, September 13th.

Evolus Stock Performance

The stock’s 50 day moving average is $12.63 and its two-hundred day moving average is $13.77. The firm has a market capitalization of $646.51 million, a P/E ratio of -11.22 and a beta of 1.32. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. increased its holdings in Evolus by 63.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 169,926 shares of the company’s stock worth $2,753,000 after purchasing an additional 65,972 shares in the last quarter. Lord Abbett & CO. LLC raised its position in Evolus by 23.4% in the 3rd quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company’s stock valued at $16,126,000 after buying an additional 188,685 shares during the last quarter. Barclays PLC lifted its stake in Evolus by 268.0% in the 3rd quarter. Barclays PLC now owns 93,662 shares of the company’s stock valued at $1,518,000 after acquiring an additional 68,213 shares in the last quarter. Geode Capital Management LLC boosted its position in Evolus by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,210,621 shares of the company’s stock worth $19,616,000 after acquiring an additional 11,027 shares during the last quarter. Finally, Jane Street Group LLC grew its stake in shares of Evolus by 47.0% during the 3rd quarter. Jane Street Group LLC now owns 91,899 shares of the company’s stock worth $1,489,000 after acquiring an additional 29,396 shares in the last quarter. Institutional investors own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.